



## Biogen to Participate in SVB Leerink's 3rd Annual CNS Forum

June 22, 2021

Cambridge, MA, -- [Biogen Inc.](#) (Nasdaq: BIIB) announced today that it will participate in SVB Leerink's 3<sup>rd</sup> Annual CNS Forum. The webcast will be live on Tuesday, June 29, at 1:50 p.m. ET. To access the live webcast, please go to the investors section of Biogen's website at [investors.biogen.com](#). An archived version of the webcast will be available following the presentation.

### About Biogen

At Biogen, our mission is clear: we are pioneers in neuroscience. Biogen discovers, develops and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies. One of the world's first global biotechnology companies, Biogen was founded in 1978 by Charles Weissmann, Heinz Schaller, Kenneth Murray and Nobel Prize winners Walter Gilbert and Phillip Sharp. Today Biogen has the leading portfolio of medicines to treat multiple sclerosis, has introduced the first approved treatment for spinal muscular atrophy, commercializes biosimilars of advanced biologics and is focused on advancing research programs in multiple sclerosis and neuroimmunology, Alzheimer's disease and dementia, neuromuscular disorders, movement disorders, ophthalmology, neuropsychiatry, immunology, acute neurology and neuropathic pain.

We routinely post information that may be important to investors on our website at [www.biogen.com](#). To learn more, please visit [www.biogen.com](#) and follow us on social media – [Twitter](#), [LinkedIn](#), [Facebook](#), [YouTube](#).

### Contact:

Karen Jewell  
Investor Relations  
Biogen  
781-464-2442